Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
17 February 2025 | Story Andre Damons | Photo Supplied
Prof Carolina Pohl-Albertyn
Prof Carlien Pohl-Albertyn is the NRF SARChI Research Chair in Pathogenic Yeasts at the UFS.

A new study by researchers from the University of the Free State (UFS), the National Health Laboratory Service, and the University of Venda has confirmed for the first time that common brown locusts are carriers of pathogenic yeasts that can cause severe infections in humans – especially in people with compromised immune systems or who are seriously ill.

The study, ‘South African brown locusts, Locustana pardalina, hosts fluconazole resistant, Candidozyma (Candida) auris (Clade III)’, highlights for the first time the presence of the pathogenic (disease-producing) fungal yeast C. auris in the digestive tract of the locusts, and shows their potential in disseminating this emerging pathogen. The research started in April 2022, when 20 gregarious (swarming) adult locusts were collected during a large locust outbreak which occurred from September 2021 to May 2022 in the semi-arid Eastern Karoo region in the Eastern Cape. The study is still under peer review.

According to Prof Carlien Pohl-Albertyn, National Research Foundation (NRF) SARChI Research Chair in Pathogenic Yeasts, three C. auris strains were isolated from three different adult locusts, two of which also harboured strains of another potentially pathogenic yeast, Candida orthopsilosis. “The fact that we were able to isolate C. auris from 15% of the sampled locusts, using non-selective media and a non-restrictive temperature of 30°C, may indicate that C. auris is abundant in the locusts and that specific selective isolation is not mandatory,” Prof Pohl-Albertyn said.

“Interestingly, C. auris was isolated from the fore- and hindgut of the locusts. Isolation from the foregut, which is dedicated to food intake and storage, filtering and partial digestion, indicates that C. auris was probably obtained by the locusts via feeding activities. Isolation from the hindgut confirms that C. auris can survive the digestive processes in the midgut and is likely to be released back into the environment via faeces.”

Healthy humans are not at great risk

One of the C. auris strains was studied in more detail. This strain was not resistant to disinfectants but showed decreased susceptibility to the common antifungal drug fluconazole. This is a characteristic of this yeast species and thus not surprising. Most of the emerging pathogenic yeasts show this intrinsic resistance. This highlights the urgent need to discover and develop new antifungal drugs.

Prof Pohl-Albertyn, also a Professor of Microbiology in the UFS Department of Microbiology and Biochemistry, says, “Healthy humans are not at great risk for infection by this yeast and there is currently no proof that ingestion may be harmful to them. This is unfortunately not the case for people with compromised immune systems or who are seriously ill. However, few susceptible people come into direct contact with the locusts in South Africa.”

She added that there are treatment options available, using other antifungal drugs, but C. auris can become resistant to all the currently available antifungal drugs.

Importance of the study

“The fact that locusts are a food source for other animals, such as birds, could lead to eventual distribution of the yeast to people. In other countries, wild locusts are a food source for humans and there more direct transmission may be possible,” Prof Pohl-Albertyn said.

She explained that this study tries to answer questions regarding the natural hosts of this emerging pathogen and how it may facilitate the spread of the pathogen to the rest of the environment. The study is one part of the puzzle regarding how new pathogens may emerge from the environment and spread to people.

“One of the questions in the field of pathogenic yeasts is how C. auris was able to emerge as a pathogen in several different countries in a relatively short period. It is well known as a hospital-acquired pathogen, but it is not known where in the environment it occurs naturally, and which environmental factors may have shaped its evolution and ability to cause human infections. This has implications for the prevention of the spread of this specific yeast species, as well as our preparedness for new pathogenic yeasts that may be emerging from the environment.”

News Archive

UFS Chemistry wins dti award
2010-11-02

At the awards ceremony are, from the left: Director-General of Trade and Industry Mr Tshediso Matona, Prof. Andreas Roodt and the Deputy-Minister of Trade and Industry, Ms Bongi Maria Ntuli.
Photo: S Osman

The research group of Prof. Andreas Roodt, Head of the Department of Chemistry at the University of the Free State (UFS) in Bloemfontein, won the first prize in the category Development of Small Medium and Micro-Enterprises (SMME) at the annual Department of Trade and Industry’s (dti) award ceremony.

Prof. Roodt received the prize for the high-technology project Development of novel nuclear pharmaceuticals in the Technology and Human Resources for Industry Programme (THRIP).

The Deputy-Minister of Trade and Industry Bongi Maria Ntuli, and Director-General Tshediso Matona presented the prize at the gala dinner held at Gallagher Estate, Gauteng in October 2010.

The dti’s Annual Technology Awards recognise excellence in research and aim to raise awareness on the benefits of using technology to improve the competitiveness of enterprises, within the local and global arena. Individuals and organisations are recognised for their efforts in advancing and promoting technology interests and emerging enterprises.

The technology awards cover the achievements of three of the dti technology programmes collectively, namely THRIP, managed by the National Research Foundation (NRF); the Support Programme for Industrial Innovation (SPII) managed by the Industrial Development Corporation (IDC); and the Small Enterprise Development Agency (seda) Technology Programme (stp).

Prof. Roodt, also vice-president of the European Crystallographic Association, who has just returned from a series of lectures abroad after being elected Fellow of the Royal Society of Chemistry in the UK, has received funding in excess of R3 million over the past two years to set up a specialised laboratory for synthesising active compounds. Key partners in this project are Dr Gerdus Kemp from PETLabs Pharmaceuticals in Pretoria; Prof. Connie Medlen (pharmacologist), recently appointed affiliate professor at UFS Chemistry; as well as Prof. Deon Visser from the Inorganic Chemistry research group at the UFS.

The research aims to produce new nuclear medicinal agents for the early diagnosis of cancer, heart and brain defects, and even HIV/ Aids.

Two doctoral students, Alice Brink and Marietjie Schutte, are currently actively involved in this project. They are the recipients of prestige scholarships introduced by the UFS Rector and Vice-Chancellor, Prof. Jonathan Jansen, under the UFS Research Initiative (the Advanced Biomolecular Systems Cluster) to complete their Ph.D. studies.

Media Release
Issued by: Lacea Loader
Director: Strategic Communication (actg)
Tel: 051 401 2584
Cell: 083 645 2454
E-mail: loaderl@ufs.ac.za  
2 November 2010

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept